Biliary Tract Cancer

Results of an ongoing, phase 2a, multiple-basket study (MyPathway) showed that dual HER2-targeted therapy with pertuzumab plus trastuzumab was well-tolerated in patients with previously treated HER2-positive metastatic biliary tract cancer.
Read More

Results from a first-in-human, phase 1 study have shown that the bispecific HER2-targeted antibody zanidatamab is well-tolerated and has antitumor activity in patients with HER2-overexpressing biliary tract cancers.
Read More

Results of the phase 2 LEAP-005 study suggest that lenvatinib plus pembrolizumab shows promising antitumor activity and manageable toxicity in previously treated patients with advanced biliary tract cancers.
Read More

Results of an open-label, phase 1/2 study indicate that addition of INCB001158 to the standard gemcitabine/cisplatin backbone was tolerable, did not result in significant additional toxicity, and showed modest clinical activity in the biliary tract cancers cohort.
Read More

Web Exclusives — October 28, 2021
On October 25, 2021, AstraZeneca announced high-level positive results from the phase 3 clinical trial TOPAZ-1, demonstrating that adding the immunotherapy durvalumab (Imfinzi) to first-line standard-of-care chemotherapy leads to a statistically significant and clinically meaningful overall survival (OS) benefit versus chemotherapy alone in patients with advanced biliary tract cancer.
Read More

At the CCA Summit during the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO), Mitesh J. Borad, MD, Associate Professor of Medicine, Mayo Clinic, Phoenix, AZ, reviewed some of the key topics presented at ASCO 2021 related to cholangiocarcinoma (CCA) and other biliary tract cancers. Before turning to the specific presentations, Dr Borad welcomed the May 28, 2021, FDA approval of infigratinib (Truseltiq) for patients with advanced or metastatic CCA and FGFR2 fusions or rearrangements. Infigratinib follows pemigatinib (Pemazyre) as the second targeted therapy now available for this patient population.
Read More

March 2021, Vol 2, No 1 — April 13, 2021
At the CCA Summit held during the 2021 ASCO Gastrointestinal (GI) Cancers Symposium, Rachna T. Shroff, MD, MS, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, Tucson, discussed 15 clinical trials that were presented at the ASCO GI Cancers Symposium on cholangiocarcinoma (CCA) and hepatobiliary diseases. She highlighted key advances related to chemotherapy, targeted therapies, and biomarkers in the management of biliary tract cancers, including CCA.
Read More

December 2020, Vol 1, No 3 — January 5, 2021
Patients with relapsed or refractory HER2-amplified biliary tract cancer have few treatment options after first-line therapy. Shubham Pant, MD, Associate Professor, Gastrointestinal Oncology, M.D. Anderson Cancer Center, Houston, TX, presented the results of a phase 1 clinical trial he and his colleagues conducted. The study examined the safety and antitumor activity of zanidatamab, a bispecific (ie, binding to 2 distinct sites on the HER2 receptor) HER2-targeted antibody. The unique antibody geometry of zanidatamab enables it to activate several mechanisms of action after binding to the HER2 receptor.
Read More

December 2020, Vol 1, No 3 — January 5, 2021
The metabolism of serotonin is dysregulated in cholangiocarcinoma (CCA) cell lines compared with normal cholangiocytes and in tissue and bile from patients with CCA.1 Telotristat ethyl (Xermelo) is a tryptophan hydroxylase inhibitor that is indicated for the treatment of patients with carcinoid syndrome–related diarrhea not well-controlled by somatostatin analog. Telotristat ethyl is currently being investigated for the treatment of patients with biliary tract cancer, including CCA tumors that express serotonin.
Read More

December 2020, Vol 1, No 3 — January 5, 2021
Cancer-related venous thromboembolism (VTE) is a significant cause of morbidity and mortality. There is a paucity of studies characterizing VTE in patients with biliary tract cancer; however, a few retrospective analyses suggest an incidence of VTE of up to 23%.
Read More

Page 2 of 4


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: